Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC

NCT01599754 is registered in ClinicalTrials.gov with SFJ Pharma Ltd. II as lead sponsor.

NCT NCT01599754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01599754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC
Lead sponsor
SFJ Pharma Ltd. II
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2012
Completion date
May 31, 2018
Enrollment
724 (actual)
Sites
106

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal carcinoma